TuHURA Biosciences Inc

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing novel technologies for cancer immunotherapies. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company is preparing to initiate a single randomized, placebo-controlled Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda, and is also developing Delta receptor technology for tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, it is developing Immune Fx and IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. Formerly known as Morphogenesis, Inc., it changed its name to TuHURA Biosciences, Inc. in December 2023. Founded in 1995, the company is based in Tampa, Florida, and operates as a subsidiary of CohBar, Inc.